Again, Anti-Inflammation treats CANCER

Dr. Weeks’ Comment:  Readers of this blog know that the cornerstone of Corrective Cancer Care™ utilizes anti-inflammatory seeds which are safe and powerful so they are very effective. Now oncologists are starting to catch on… but they offer TOXIC anti-inflammatory agents – Celebrex (cousin to the banned toxic Vioxx) and now Non Steroidal Anti-Inflammatory Agents (NSAIDs) which, like Tylenol, are toxic to the liver and kidney. The future of cancer care is anti-inflammation and immune stimulation.   So Eat the Seeds if you want to Survive and Thrive.


Use of nonsteroidal anti-inflammatory drugs predicts improved patient survival for PIK3CA-altered head and neck cancer

Matthew L. Hedberg, et al 


PIK3CA is the most commonly altered oncogene in head and neck squamous cell carcinoma (HNSCC). We evaluated the impact of nonsteroidal anti-inflammatory drugs (NSAIDs) on survival in a PIK3CA-characterized cohort of 266 HNSCC patients and explored the mechanism in relevant preclinical models including patient-derived xenografts. Among subjects with PIK3CA mutations or amplification, regular NSAID use (≥6 mo) conferred markedly prolonged disease-specific survival (DSS; hazard ratio 0.23, P = 0.0032, 95% CI 0.09–0.62) and overall survival (OS; hazard ratio 0.31, P = 0.0043, 95% CI 0.14–0.69) compared with nonregular NSAID users. For PIK3CA-altered HNSCC, predicted 5-yr DSS was 72% for NSAID users and 25% for nonusers; predicted 5-yr OS was 78% for regular NSAID users and 45% for nonregular users. PIK3CA mutation predicted sensitivity to NSAIDs in preclinical models in association with increased systemic PGE2 production. These findings uncover a biologically plausible rationale to implement NSAID therapy in PIK3CA-altered HNSCC.

Leave a Comment

Your email address will not be published. Required fields are marked *